Pharmaceutical

AbbVie is planning to build a 185-acre pharmaceutical campus in Durham, N.C. The $1.4 billion development will integrate AI with advanced manufacturing and laboratory technologies to enhance quality control and support the company’s pipelines of immunology, neuroscience, and oncology medicines. Comprising approximately 440,000 sf, the first phase of construction will begin in 2026 to create manufacturing plants for small volume parenteral (SVP) drug products.

CordenPharma Colorado is partnering with BioMed Realty to expand its peptide development capabilities in Boulder with the lease of a 64,000-sf facility in Flatiron Park. Located near the CDMO’s large-scale peptide manufacturing hub, the state-of-the-art building will accommodate process development and analytical services, enabling seamless integration of advanced peptide API (Active Pharmaceutical Ingredient) creation from production to commercialization.

AbbVie is planning a $380 million expansion of its headquarters campus in North Chicago, Ill. Construction will begin in spring of 2026 on two plants for the production of active pharmaceutical ingredients (APIs). Enabling the creation of innovative treatments for neurological conditions and obesity, the next-generation facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to maximize purity, efficacy, and operational efficiency. Full production is expected to commence in 2029.

Johnson & Johnson is investing over $1 billion to create a next-generation cell therapy manufacturing facility in Lower Gwynedd Township, Pa. The state-of-the-art hub is part of a $55 billion commitment to expand the company’s infrastructure and capacity in the United States by early 2029, and supports plans to produce the vast majority of J&J’s innovative medicines domestically to meet the needs of U.S. patients.

Novartis broke ground in February of 2026 on the Biomedical Research Center in San Diego. This nexus for innovation will enable end‑to‑end discovery across key disease areas and technology platforms, joining seamlessly with existing sites including Cambridge, Mass., and Basel, Switzerland. Representing an investment of $1.1 billion, the 466,000-sf facility will drive advances in neuroscience, global health, regenerative medicine, and oncology and age-related diseases.

Roche will expand its leased presence on Harvard University’s Enterprise Research Campus from 30,000 sf to 100,000 sf in Breakthrough Properties’ One Milestone property in Boston. Located in the thriving Allston neighborhood, the Roche Genentech Innovation Center will bring together cardiovascular, renal, and metabolism experts with data science and AI specialists to accelerate drug discovery and development. Construction is nearly complete and phased occupancy will commence in mid-2026.

Eli Lilly and Company will begin construction in mid-2026 on a $3.5 billion facility in Upper Macungie Township, Pa., for the manufacture of injectable medicines and devices. The project represents the largest investment made by a life sciences company in the state’s history, and will be the largest development ever to rise in the Lehigh Valley. The seven-building complex will enable the production of next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1, and glucagon triple hormone receptor agonist.

Genentech, an independent subsidiary of Roche, is expanding the initial investment in its new biomanufacturing facility in Holly Springs, N.C., from $700 million to approximately $2 billion. Originally envisioned as a 700,000-sf complex, the project will now deliver increased production volume and scale capacity, significantly enhancing the company's U.S. supply chain.

Eli Lilly and Company is planning to construct an advanced manufacturing facility in Huntsville, Ala. Representing a total investment of $6 billion, the multibuilding campus will offer over 1 million sf of space for production, laboratories, packaging, logistics, and utilities. The sophisticated development will manufacture active pharmaceutical ingredients and small molecule synthetic and peptide medicines, including the company’s first oral small molecule GLP-1 receptor agonist, orforglipron.

The University of Virginia is constructing the $350 million Paul and Diane Manning Institute for Biotechnology in Charlottesville to catalyze breakthroughs in the fields of cellular therapy, gene therapy, nanotechnology, and drug delivery. Designed by Elkus Manfredi Architects, the flexible building will provide 355,809 sf of space for leading-edge laboratories, core facilities, advanced manufacturing suites, and clinical environments.

Breakthrough Properties completed construction in November of 2025 on One Helix in the Netherlands. Strategically sited within the campus of Amsterdam University Medical Center, the purpose-built research facility will leverage connections with the surrounding academic, life sciences, and biopharma ecosystem to catalyze life-changing scientific advancements. The 70,126-sf building was designed by UNStudio to offer world-class laboratory and office environments that foster collaboration and innovation.

When it was proposed in 2019, repurposing underutilized space at the University of Georgia for an industry partner’s fermentation lab appeared to be a good deal for everyone involved. It was a win for the pharmaceutical company that wanted to contract with the university to help it develop new products and needed a fermentation lab that met, at a minimum, biosafety level 2 (BSL-2) standards. It was a plus for staff at the university’s Bioexpression and Fermentation Facility who would perform the work. It represented an advance for the university that wanted to form new industry relationships and had available space at its Athens, Ga. campus inside the Animal Health Research Center (AHRC). And it was a win for the AHRC, a 75,000-sf biocontainment facility that would host a new industry partner in addition to other laboratories performing BSL-2, animal biosafety level 2 (ABSL-2), biosafety level 3 (BSL-3), animal biosafety level 3 (ABSL-3), and animal biosafety level 3-agricultural (ABSL-3Ag) research work.

Eli Lilly and Company is constructing the $4.5 billion Lilly Medicine Foundry in Lebanon, Ind. The 1.2 million-sf center will combine research and advanced manufacturing with the latest technology to innovate new production methods and scale global access to medicines for clinical trials. Featuring a flexible layout, the seven-building complex will create various molecular therapies, including drug substances for small molecules, biologics, and nucleic acid therapeutics. 

Merck opened a filter and membrane manufacturing facility in October of 2025 in Cork, Ireland. Offering 32,291 sf of cleanroom space, the €150 million ($174.5 million) building will meet global demand in the production process of vaccines and life-changing biomedical treatments, including monoclonal antibodies and cell and gene therapies. By locating these expanded manufacturing capacities in Europe, Merck aims to reduce cross-border dependencies and ensure reliable access to critical filtration technologies.

FUJIFILM Biotechnologies opened a $3.2 billion pharmaceutical manufacturing facility in September of 2025 in Holly Springs, N.C. Integrating leading-edge equipment and technologies, the sophisticated development features eight 20,000-liter bioreactors for the production of bulk drug substances and innovative therapies. Johnson & Johnson and Regeneron have signed 10-year contracts to secure space at the 1.3 million-sf campus, which represents the largest end-to-end cell culture CDMO hub in North America.